BRUSSELS, December 20 (Reuters) – Novavax (NVAX.O) is expected to start delivering its COVID-19 vaccines to the European Union in the first quarter of 2022, a European source said, as experts from the organization region drug regulators met on Monday. to decide whether or not to approve the shot.
The European Commission made no immediate comment and the US biotech company was not immediately available for comment. The European source declined to be identified as she was not authorized to speak to the media.
If approved, the two-dose vaccine, branded Nuvaxovid, would be the fifth coronavirus vaccine to hit the EU market and will arrive as the Omicron coronavirus variant spreads.
Earlier in the year, Novavax told the European Union that it plans to start making the first small shipments of its vaccine for the block towards the end of this year, with the bulk of the supplies in 2022, a an EU official told Reuters in May. Read more
The European Commission and the company signed a contract in August for delivery of up to 200 million doses, half of which are optional.
Register now for FREE and unlimited access to Reuters.com
Register
Report by Francesco Guarascio in Brussels; Written by Joséphine Mason in London; Editing by Toby Chopra, Jane Merriman and Susan Fenton
Our Standards: Thomson Reuters Trust Principles.